GSK plc (LON:GSK - Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 1,360 ($17.50) and last traded at GBX 1,361.14 ($17.52), with a volume of 53444816 shares trading hands. The stock had previously closed at GBX 1,397 ($17.98).
Analyst Ratings Changes
Several brokerages have recently commented on GSK. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Monday, July 29th. Berenberg Bank reissued a "buy" rating and issued a GBX 1,820 ($23.42) price objective on shares of GSK in a research note on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a GBX 1,850 ($23.81) price target on shares of GSK in a research note on Tuesday, September 3rd. Finally, Shore Capital restated a "buy" rating on shares of GSK in a research note on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of GBX 1,842.50 ($23.71).
View Our Latest Stock Report on GSK
GSK Stock Performance
The stock has a market cap of £55.88 billion, a PE ratio of 1,207.08, a P/E/G ratio of 1.24 and a beta of 0.31. The stock has a 50-day simple moving average of GBX 1,512.80 and a 200-day simple moving average of GBX 1,583.74. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.
GSK Announces Dividend
The firm also recently disclosed a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be paid a dividend of GBX 15 ($0.19) per share. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK's payout ratio is presently 5,309.73%.
Insiders Place Their Bets
In other GSK news, insider Jonathan Symonds acquired 7,150 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of GBX 1,394 ($17.94) per share, for a total transaction of £99,671 ($128,260.20). In other GSK news, insider Jonathan Symonds purchased 7,150 shares of GSK stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of GBX 1,394 ($17.94) per share, for a total transaction of £99,671 ($128,260.20). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the business's stock in a transaction dated Monday, September 23rd. The stock was purchased at an average price of GBX 2,051 ($26.39) per share, for a total transaction of £9,147.46 ($11,771.28). Insiders acquired 7,604 shares of company stock worth $10,893,038 over the last three months. Insiders own 1.61% of the company's stock.
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
